27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- GSK plc (NYSE:GSK) announced positive results from a Phase 2a study demonstrating that GSK3036656, an investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.
- The trial included participants with drug-susceptible pulmonary tuberculosis (TB).
- Earlier this year, GSK committed to investing £1 billion over the next decade to accelerate R&D on infectious diseases, including TB, that disproportionately impact lower-income countries.
- The anti-mycobacterial activity was demonstrated in reducing the number of viable TB cells which can multiply (colony forming units - CFU) and an increase in the time to detect bacterial growth in culture (time to positivity - TTP).
- In addition, PET CT imaging of the lungs showed a reduction in TB disease over 14 days in all participants taking GSK3036656 30mg.
- The investigational antitubercular agent will be tested in Phase 2b/c studies in different drug regimens to determine the appropriate partner agents to complement its anti-TB action and the optimal regimen durations.
- Price Action: GSK shares are up 3.51% at $32.68 on the last check Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!